Arrowhead Research | ARWR - Stock


Arrowhead Research reported $-173.08M in Stock for its fiscal quarter ending in December of 2024.





Stock Change Date
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Anika Therapeutics USD 28.56M 5.73M Jun/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Incyte USD 112.54M 3.08M Jun/2026
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
Ligand Pharmaceuticals USD 13.27M 4.14M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 280M 134M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Novartis USD 6.22B 66M Jun/2026
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
TG Therapeutics USD 147.97M 18.94M Jun/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026